Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male

NCT07310420 2026-06-03

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1 Recruiting

88 enrolled

Breast

Breast Neoplasms

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3 Active not recruiting

608 enrolled 18 charts

Breast

Breast Neoplasms

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

716 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05870579 2026-05-27

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast

Breast Neoplasms

NCT06953882 2026-05-26

SELECT

Phase 2 Recruiting

140 enrolled

Breast

HER2 Negative Breast Cancer

NCT07287098 2026-05-22

preEMBER

Phase 2 Not yet recruiting

600 enrolled

Breast

Breast Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Phase 1/2 Not yet recruiting

100 enrolled

BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled 14 charts

Breast

Advanced Breast Cancer

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast

Breast Neoplasms

NCT07460752 2026-03-10

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

Phase 2 Not yet recruiting

98 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

74 enrolled

Breast

Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

Phase 2 Recruiting

75 enrolled

Breast

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

200 enrolled

Breast

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05122377 2026-01-06

RWE About QOL and Compliance of Patients With OFS in China

Completed

562 enrolled

Breast

Breast Neoplasms, Patient Compliance

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast

Breast Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2 Completed

327 enrolled

Breast

Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

Phase 2 Recruiting

87 enrolled

Breast

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

Phase 2 Completed

376 enrolled 17 charts

Breast

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Phase 2 Not yet recruiting

288 enrolled

Breast

HER2-positive Breast Cancer

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 3 Completed

315 enrolled 11 charts

Breast

Breast Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

Clinical Trials

Adjuvant WIDER

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

FASCINATE-N

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

SELECT

preEMBER

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

A Study of Lerociclib in Participants With Advanced Breast Cancer

Roll-over Study to Allow Continued Access to Ribociclib

CARABELA

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

PETREMAC

e3

BYLieve

RWE About QOL and Compliance of Patients With OFS in China

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

EVANGELINE

AMALEE

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

AMEERA-5

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score